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ABSTRACT 
 prodrugs are bioreversible derivatives of drug molecules that undergo 
intermolecular or intramolecular reactions by enzymatic or chemical 
biotransformation in the human body to give the corresponding active 
parent drugs and a non-toxic promoiety. Prodrugs have been 
extensively and successfully used as a chemical tool for modification 
of the physicochemical, pharmacokinetic as well as pharmacodynamic 
characteristics of commonly used drugs and new drugs.This mini 
review focuses on the design, synthesis and pharmacological effects of 
several prodrugs and codrugs of the non-steroidal anti-inflammatory 
(NSAIDs), mefenamic acid. Exploitation of the prodrug approach has 
the potential to achieve a reduction of mefenamic acid GI (gastro-
intestinal) intolerance, enhance its bioavailability, mask its unpleasant  
sensation and prolong its duration of action. In addition, utilizing the prodrug concept migh 
enhance the bioavailability of the counter partner drug of mefenamic acid codrug by 
increasing its lipophilicity. 
 
KEYWORDS: Anti-inflammatory drugs, Mefenamic acid prodrugs, Mefenamic acid 
codrugs, Prodrugs chemical approach, NSAIDs drugs, Prodrugs catalyzed by enzymes. 
 
 
 
World Journal of Pharmaceutical Research 
                                                                                                                                    SJIF Impact Factor 5.990 
Volume 4, Issue 6, 2408-2429.            Review Article              ISSN 2277– 7105
  
Article Received on 
20 April 2015, 
Revised on 10 May 2015, 
Accepted on 31 May 2015 
 
DOI:10.20959/wjpr20156-3765 
 
*Correspondence for 
Author 
Dr. Rafik Karaman 
Pharmaceutical Sciences 
Department, Faculty of 
Pharmacy, Al-Quds 
University, Jerusalem, 
Palestine. 
 
 
 
  
 
 
   
 
       
www.wjpr.net                                   Vol 4, Issue 07, 2015                                            
            
 
 
2409 
Rafik et al.                                                             World Journal of Pharmaceutical Research 
INTRODUCTION                                                                                                                                                     
Prodrugs are molecules which are lacking any pharmacodynamic properties and therefore are 
not biologically active by themselves, however, they exert a therapeutic effect when they are 
inter- or intraconverted to their active parent drugs by chemical or enzymatic processes.
[1]
 
 
Prodrug design is an essential part of the drug discovery and development. Prodrugs can offer 
a variety of advantages over their parent active forms; such advantages include an increased 
in solubility, enhanced stability, improved bioavailability, reduced side effects, masked 
unpleasant taste and odor and better selectivity.
[2] 
 Therefore, utilizing the prodrug approach 
might improve the physicochemical properties of a drug and hence increase its bioavailability 
and therapeutic efficiency.
[1, 3]
 
 
The first time the prodrug concept used was in the middle of the twentieth century by Parke- 
Davis Company during a study conducted on a modification of chloramphenicol structure for 
improving its unpleasant taste and poor solubility in water. As a result of this study 
twochloramphenicol prodrugs were synthesized: chloramphenicol sodium succinate having 
goodwater solubility for use in IV, IM and ophthalmic administration, and chlorampheni 
colpalmitate to be administered in the form of suspension for pediatrics and geriatrics.
[4, 5] 
 
The conventional and accepted method for prodrugs classification is based on the drug’s 
derivatization and linker’s type. Using this method prodrugs are divided into two sub major 
classes: (i) carrier-linked prodrugs, in this class the linker is covalently attached to the active 
drug, however, drug-linker linkage has to be accessible to undergo cleavage via enzymatic or 
chemical processes to yield the active parent drug and a nontoxic and non-immunogenic 
linker which must be ready for removal by in vivo elimination.
[6, 7]
 This class is usually 
subdivided into three sub-classes: (1) bipartite which consists of one linker (promoiety) 
attached directly to the active parent drug, (2) tripartite which involves a spacer or connecting 
moiety between the drug and linker. Generally, known bipartite prodrugs are stable, however, 
in some examples they may suffer instability due to the nature of the drug linker linkage and 
(3) mutual prodrugs, which involve two drugs linked together. 
 
(ii) Bioprecursors which are molecules lacking any therapeutic effect however, upon in vivo 
metabolism they furnish new entities that may be active or further may metabolized to active 
metabolites. Examples for such class might involve an amine which is metabolized to 
aldehyde and the latter into carboxylic acid. In this class of prodrugs there is no linker 
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(carrier) but the bioprecursors should be readily metabolized to induce the appropriate 
functional groups.
[1, 4, 8] 
 
During the past two decades extensive research has been done to promote and accelerate the 
use of prodrugs to replace a number of marketed drugs having low bioavailability as a result 
of one or more pharmacokinetic barriers. The prodrug approach has been successfully and 
significantly applied to a wide range of drugs. Statistics have shown that currently more than 
10% of the world-wide drugs available in the pharmaceuticals market can be classified as 
prodrugs. In addition, it is estimated that about 20% of drugs having small molecular weights 
approved during the period 2000-2008 were prodrugs, and in the year 2008 alone, more than 
33% of approved drugs were prodrugs.
[9]
 
 
Non–steroidal anti-inflammatory drugs (NSAIDs) are among the most widely over the 
counter (OTC) and prescribed drugs used throughout the world. Historically, the NSAIDs had 
their origin in the serendipitous discovery of some plants where the extracts of those plants 
had been applied for pain relief, fever and inflammation conditions.
[10, 11]
 
 
NSAIDs exert their therapeutic effects by inhibiting the synthesis of prostaglandins (PGs) by 
non-selectively blocking cyclooxygenases 1 and 2 (COX-1 and COX-2). COX-1 is 
constitutively expressed in stomach to provide cytoprotection in the GIT. COX-2 is inducible 
and plays a major role in prostaglandin biosynthesis in inflammatory cells.
[11]
 
 
In the past few years, epidemiological studies have indicated that NSAIDs are 
neuroprotective
[12]
 therefore, their prolonged use reduces the risk of Alzheimer’s.[13]  In 
addition, recent clinical studies have provided evidence that NSAIDs are promising 
anticancer agents as well.
[14, 15]
 
 
Pain sensation can be associated with different disease statements. Women in the world suffer 
from extensive pain during their menstrual cycle which is accompanied with heavy bleeding. 
NSAIDs have been shown to reduce blood loss by 20-49% and can be used for an indefinite 
number of menstrual cycles.
[16]
 
 
Therefore, the relationship between oral intake of NSAIDs and gastrointestinal (GI) 
sideeffects, in some cases life threatening conditions, limits the NSAIDs clinical usefulness. 
Non-steroidal anti-inflammatory drugs with tranexamic acid are the first line therapy to treat 
pain associated with bleeding. It has been shown to be effective in reducing heavy menstrual 
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bleeding and pain especially in women using intrauterine devices (IUDs). There are potential 
advantages in giving such co-administered drugs having complementary pharmacological 
activities in the form of a single chemical entity in order to increase patient 
compliance.Abnormal uterine bleeding and pain are the most common medical reasons for 
prematurediscontinuation of the intrauterine device (IUD). The IUD is the most common 
method ofreversible contraception worldwide (147 million current users), so premature 
discontinuation affects large numbers of women. Each year, an estimated 40 million women 
have an IUD inserted. From 5% to 15% of women discontinue IUD use within one year 
because ofbleeding or pain.
[16]
 
 
On other hand, mefenamic acid and diclofenac have unpleasant bitter taste associated with 
numbness of the tongue, which limits their use as an oral dosage form especially in pediatric 
and geriatric patients.
[17]
  Conventional taste masking methods such as the use of sweeteners, 
amino acids and flavoring agents alone are often inadequate in masking the taste of highly 
bitter drugs. Another approach is to improve the unpleasant taste by masking the functional 
group in the drug that is responsible for its bitterness.
[18]
 
 
NSAIDs can be classified based on their chemical structure or mechanism of action:   
• Salicylates. 
• Propionic acid derivatives. 
• Acetic acid derivatives. 
• Selective COX-2 inhibitors. 
 
The most prominent members of the NSAIDs are mefenamic acid, 1 (Figure 1), diclofenac 
potassium or sodium, 2(Figure 1), ibuprofen, 3(Figure 1), ketoprofen, 4(Figure 1), naproxen, 
(Figure 1) aspirin, 6(Figure 1), celecoxib, 7(Figure 2), etoricoxib,  8 Figure 2). parecoxib, 9 
(Figure 2), and others. 
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Figure 1: Chemical structures of NSAIDs 1-6 
 
Upper gastro intestinal tract (GIT) injury constitutes the most frequent of all adverse 
reactions of NSAIDs and often these reactions lead to GIT ulceration and hemorrhage. Gastro 
intestinal (GI) mucosal injury produced by NSAIDs is generally believed to be caused by two 
different mechanisms: a local action exerted by direct contact of a drug with gastric mucosa 
caused by the free carboxyl acid group and a generalized systemic action following 
absorption which is believed to be caused by inhibition of the COX 1, a constitutive form of 
COX.
[19]
 Intolerance of GI side effects leads to withdrawal rates of  about 10% of NSAIDs 
users. Furthermore, nonselective NSAID users are four to eight times more likely to develop 
gastro duodenal ulcers during therapy.
[20]
 
 
Not widely appreciated, NSAIDs use results in death as well. Few studies have estimated 
mortality resulting from GI complications of NSAIDs. Among the available reports, 
estimates attributable to NSAIDs have widely varied from 3,200 to higher than 16,500 deaths 
per year in the United States (Figure 3).
[21]
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Figure 2: Chemical structures of NSAIDs 7-9. 
 
     
Figure 3: Mortality statistics for different drugs and diseases in the united states 
1997.
[21] 
 
The world market for NSAIDs is approximately $8 billion. The cost of treating 
NSAIDsrelated gastrointestinal adverse effects almost certainly exceeds this amount. The 
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annual cost of treating NSAID gastropathy in rheumatoid arthritis patients in the USA, for 
example, have been reported to exceed $4 billion.
[22]
 
 
In general, different chemical modifications have been made for obtaining NSAIDs prodrugs 
to overcome the side effects associated with the use of NSAIDs such as the GI side effects. 
These methods include: 
 
(1) Ester and amide prodrugs; NSAIDs ester prodrugs are made via a reaction of the 
carboxylic group of the NSAID drug (via acyl halide) and an alcohol such as ethanol, 
isopropyl alcohol and etc.. Similarly, amide prodrugs have also been synthesized from the 
reaction of the carboxylic group of the NSAID (via acyl halide) with an amine. The amide 
prodrugs are relatively more stable prodrugs in the stomach than their corresponding esters as 
amidases which catalyze the hydrolysis of amides are present only in the intestine, (2) 
anhydride prodrugs of NSAIDs; since the hydrolysis of ester and amide prodrugs is 
dependent on the activity of esterases and amidases, respectively, and this catalysis is varied 
upon the time and target of the drug’s administration (variable bioavailability), anhydride 
prodrugs of carboxylic acid drugs may solve this problem. Dissimilar to ester linkage, the 
anhydride linkage is more labile to hydrolysis and undergoes cleavage to its corresponding 
carboxylic acid in a controlled and predictable manner and it has shown less sensitivity to 
cleavage catalyzed by enzymes than its corresponding esters and amides,
[23]
 (3) mutual 
prodrugs of NSAIDs: they normally comprise of two biologically active agents coupled 
together so that each of both drugs acts as a promoiety for the other and vice versa, (4) the 
NSAID coupling with amino acids and (5) glucosamine conjugate prodrug of NSAIDs. 
 
Mefenamic acid (MA) (1 in Figure 3), is a compound belonging to the family of Naryl 
anthranilic acid. It is one among the most widely used NSAIDs having both antiinflammatory 
and analgesic activities. It has short half-life of 2 hours and 90% bioavailability. The main 
side effect of using mefenamic acid is an increased risk of serious gastrointestinal adverse 
events including bleeding, ulceration, and perforation of the stomach or intestines, which can 
be in some cases fatal. 
 
During the past seventeen years attempts have been made to overcome the gastrointestinal 
side effects associated with the use of mefenamic acid. In 1997 Jilani et al. have synthesized 
several hydroxyethyl esters of diclofenac and mefenamic acid and studied their stability in 
1N HCl, buffer pH 7.4 and human plasma. Their study revealed that mefenamic acid 
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prodrugs were much more stable than their corresponding diclofenac prodrugs. The t1/2 
values for mefenamic acid prodrugs were 38 hours in buffer pH 10 and 7.8 hours in plasma 
and that of diclofenc prodrugs were 22 hours and 1.12 hours, respectively. Based on this 
result they concluded that mefenamic ester prodrugs are not suitable for use as prodrugs due 
to their high stability in plasma.
[24]
 
 
In 2002, Tantishaiyakul et al. have synthesized a mefenamic-guaiacol ester prodrug by 
reacting mefenamic acid, guaiacol, N, N′-dimethylaminopyridine, and N, N′- 
dicyclohexylcarbodiimide. The physicochemical properties, stability and transport across 
Caco-2 monolayers for the synthesized prodrug were researched. The prodrug has shown to 
be completely stable in aqueous buffer solutions of pH 1-10. However, it underwent 
hydrolysis in the presence of porcine liver esterase and Caco-2 homogenate. The transported 
amount of the ester was 14.63% after 3 hours with a lag time of 23 minutes. The Papp for the 
ester was 4.72 × 10-6 cm s-1. This value suggests that the prodrug absorption was 
moderate.
[25] 
 
In 2005, Almasirad et al. have made a number of mefenamic acid prodrugs by which the non-
steroidal anti-inflammatory drug is attached to N-Arylhydrazone derivative. The aim of their 
study was to obtain new compounds having analgesic and anti-inflammatory activity without 
GI side effects. The synthesized prodrugs were tested for analgesic and anti-inflammatory 
activities by abdominal constriction (writhing test) and carrageenan-induced rat paw edema 
tests, respectively. Their study results revealed that most of the synthesizedprodrugs induced 
significant reduction in the writhing response compared to the control samples.
[26]
 
 
In 2005, Khan et al. reacted mefenamic acid with 1, 2, 3-trihydroxy propane 1, 3- 
dipalmitate/stearate to provide new mefenamic acid ester prodrugs. The aim of their study 
was to make novel mefenamic acid prodrugs lacking the gastrointestinal side effect 
associated with their parent drug, mefenamic acid. The synthesized prodrugs were tested for 
gastric toxicity, anti-inflammatory activity by the carageenan induced paw oedema test and 
analgesic activity by the acetic acid induced writhing method. The cleavage rate of the ester 
prodrugs to their parent active drug was studied at pH 3, 4, 5 and 7.4 and monitored by HPLC 
method. The kinetic results revealed very low hydrolysis rate at pH 5 when compared to pH  
7.4. This result indicates that the drug release from the prodrugs in the pH of stomach was 
negligible; however, the release of mefenamic acid at pH 7.4 was in adequate amounts.
[27] 
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In 2007, Dev et al. have synthesized mefenamic acid-β-cyclodextrin prodrug. The primary 
hydroxy group of β-cyclodextrins was used to block the free acid group of mefenamic acid. 
The synthesis consisted of several protection and deprotection steps. 
 
The study results demonstrated that the mefenamic acid-β-cyclodextrin prodrug has retained 
its pharmacological activity as was evident by the percentage inhibition of oedema and in 
acetic acid induced writhing method and comparison with the activity of its active parent 
drug. In addition, the study showed that the maximum activity of the ester prodrug was 
obtained after 6 hours indicating that there is no drug absorption in the stomach. Further, in 
vitro studies showed the ester to be completely stable in simulated gastric and intestinal fluid 
whereas it underwent complete hydrolysis in rat faecal contents representing the colon. 
 
Ulcerogenicity studies showed that the ester prodrug is not ulcerogenic indicating that 
masking the carboxyl group in mefenamic acid is a good approach to reduce the 
ulcerogenicity, a major side effect of the active parent drug, mefenamic acid.
[28] 
 
In 2009, Rasheed et al. have synthesized mefenamic amide prodrugs by an amidation 
reaction of methyl esters of amino acids such as histidine and tryptophan with mefenamic 
acid. The goal of their study was to mask the free hydroxyl group of mefenamic acid which is 
responsible for the adverse effects of gastrointestinal origin associated with the use of the 
NSAID drug. The hydrolysis rates, antiinflammatory and analgesic activities as well as ulcer 
index of the synthesized amide prodrugs were investigated. The results indicated marked 
reduction of ulcer index and comparable anti‐inflammatory activity of the prodrugs as 
compared to mefenamic acid. In addition, the amide prodrugs showed excellent 
pharmacological response and encouraging hydrolysis rate both in SIF and SIF+ 80% human 
plasma. Based on this result the authors concluded that both amide prodrugs are more 
efficient than their active parent drug and are advantageous due to the fact that they possess 
lesser gastrointestinal side effects than mefenamic acid.
[29]
 
 
In 2010, Rasheed et al. have synthesized two mefenamic acid-amide prodrugs, mefenamic 
acid-tyrosine and mefenamic acid-glycine via multi-step synthesis which involved protection 
and deprotection reactions. Pharmacological activity test and kinetic studies on both prodrugs 
were carried out. The two prodrugs kinetic studies were accomplished in simulated gastric 
fluid, simulated intestinal fluid, and 80% plasma. In addition, the analgesic, anti-
inflammatory, and ulcerogenic activities for both prodrugs were evaluated. Mefenamic acid- 
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glycine prodrug showed analgesic activity of 86%, and both mefenamic acid-tyrosine and 
mefenamic acid-glycine prodrugs showed more efficient anti-inflammatory activity (74% and 
81%, respectively) than that of their parent drug, mefenamic acid (40% ). Moreover, the 
study indicated that the average ulcer index of the two newly synthesized prodrugs was lower 
(9.1 and 4.5) than that of mefenamic acid (24.2). Based on the study results the authors 
concluded that both prodrugs are more efficient than mefenamic acid and are advantageous 
since their gastrointestinal side effects are lesser than of their parent drug, mefenamic acid.
[30] 
 
In 2011, Uludag et al. have synthesized ibuprofen, ketoprofen, and mefenamic acid ester and 
amide prodrugs and they investigated their pharmacological activities and stability in 
physiological media. Their findings revealed that the synthesized prodrugs were completely 
stable in simulated gastric (SGF, pH 1.2) and intestinal fluids (SIF, pH 6.8). 
 
Furthermore, they found that these prodrugs were more lipophilic than their parent active 
drugs, thus resulting in higher absorption than their parent drugs. Based on the lack of the 
hydrolysis of these prodrugs by esterases and amidases they concluded that these NSAID 
derivatives have potent analgesic and anti-inflammatory activity themselves and lack any 
gastrointestinal side effects (non-ulcerogenic). These results were supported by docking 
experiments of the synthesized prodrugs with the active sites of esterases and amidases which 
revealed a strong binding between the prodrugs and enzymes
[31]
 
 
In 2011, Velingkar et al. synthesized a number of mefenamic acid codrugs with and without 
spacer. The synthesized codrugs were tested for anti-inflammatory activity by carrageenan 
induced rat paw edema method; for analgesic activity by Eddy’s hot plate and tail-flick 
method; and for ulcerogenicity and acute oral toxicity. The tests results for the codrugs 
revealed efficient analgesic and anti-inflammatory activity and a lack of ulcerogenicity. 
Hydrolysis studies demonstrated that the codrugs were stable at pH 1.2, indicating a lack of 
cleavage of the codrugs in the stomach. However, in human plasma (pH 7.4) the codrugs 
released 80% of the parent drug upon hydrolysis, whereas much lower percentage of the drug 
was released in aqueous buffer of 7.4, suggesting that the rate of hydrolysis in human plasma 
was markedly accelerated when compared to that in aqueous buffers.
[32]
 
 
In 2012, Mahdi et al. have synthesized a number of NSAIDs-gabapentin codrugs by which 
the two active parent drugs were connected by glycol spacers with the aim to reduce the 
gastrointestinal adverse effects associated with the use of NSAIDs. The hydrolysis of the 
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ester bond connecting the two drugs via glycol in two different non enzymatic buffers at pH 
1.2 and 7.4, as well as in 80% human plasma was monitored by HPLC. The codrugs 
connected via ethylene glycol spacers showed complete stability at buffer solutions with half-
lives ranging from about 8–25 hours, whereas they underwent 49%–88% hydrolysis (within 2 
hours) in 80% human plasma. The kinetic study results of some of the codrugs indicate that 
these compounds may be stable during their passage through the GIT until reaching the blood 
circulation.
[33]
 
 
In 2013, Shah et al. synthesized a novel codrug consisting of paracetamol and mefenamic 
acid with the aim to reduce the ulcererogenic adverse effects associated with the use of 
NSAIDs. The codrug was completely characterized by standard methods, its stability at 
different pH values was investigated and its pharmacological properties were evaluated. 
 
The kinetic study of the codrug was followed by HPLC at pH 2, pH 7.4 as well as in human 
plasma. The kinetics results showed the codrug to be stable at pH 2 and pH 7.4, however, it 
underwent cleavage to the parent drugs in human plasma with hydrolysis rate of 1.8908 x 
10
4
s-
1
 and half-life (t1/2) of 61.07 minutes, indicating rapid hydrolysis in plasma to release 
the two parent drugs. The pharmacological activities (anti-inflammatory, analgesic and 
ulcerogenic) were evaluated for the codrug. The ulcerogenic reduction in terms of gastric 
wall mucosa, hexosamine and total proteins were also determined in glandular stomach of 
rats. The results revealed that the codrug has an ulcer index lower than the parent drug, 
indicating low ulcerogenic side effects.
[34]
 
 
In 2014, Dhokchawle et al. have synthesized a number of mefenamic acid prodrugs by which 
the free carboxyl group in mefenamic acid was connected via a covalent bond with natural 
compounds, eugenol and vanillin. The synthesized ester prodrugs were fully characterized by 
standard methods and by solubility studies, partition coefficient and hydrolytic studies. The 
synthesized prodrugs were tested for their anti-inflammatory analgesic and ulcerogenic 
activity. The tests results revealed that the synthesized prodrugs have shown retention of the 
anti-inflammatory activity with a reduced ulcerogenicity when compared to their active 
parent drug, mefenamic acid.
[35]
 
 
In 2014, Kemisetti et al. have synthesized mefenamic acid prodrugs by which the NSAID 
drug was covalently attached to either polyethylene glycol 1500 or polyethylene glycol 6000 
via a glycine spacer. The synthesized prodrugs were fully characterized and their hydrolysis 
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at buffers of pH 1.2 and 7.4 was investigated. In addition, their anti-inflammatory activity 
using Carrageenan induced rat paw edema method and ulcerogenicity using Pylorus ligation 
method were tested. The study results demonstrated that the hydrolysis rates of the prodrugs 
at pH 7.4 were higher than that at pH 1.2 and the anti-inflammatory activity of the prodrugs 
was comparable to that of their active parent drug, mefenamic acid. 
 
Based on these results the authors concluded that the synthesized prodrugs possess anti-
inflammatory activity as well as good ulcer protecting activity and can be used as a better 
replacement to their parent NSAID drug. 
[36] 
 
The prodrug chemical approach involving enzyme catalysis has many disadvantages related 
to many intrinsic and extrinsic factors that can affect the process. For instance, the activity of 
many prodrug-activating enzymes may be varied due to genetic polymorphisms, age-related 
physiological changes, or drug interactions, leading to variation in clinical effects. Therefore, 
there is a need to develop prodrugs that have the potential to undergo intraconversion to their 
parent drugs via intramolecular reaction and without a need of enzyme catalysis. 
[37-39]
 
 
Recently we have been engaging in unraveling the mechanisms of a number of enzyme 
models for allowing the design of efficient chemical devices to be utilized as prodrug linkers 
that can be covalently attached to commonly used drugs which can chemically, and not 
enzymatically, be converted to release the active drugs in a controlled manner.
[40-75]
 
 
For example, investigating the mechanism for a proton transfer in Kirby’s N-alkylmaleamic 
acids (enzyme model) has assisted in the design and synthesis of several prodrugs such as the 
anti-bleeding agent, tranexamic acid, 
[76]
 the anti-viral acyclovir, 
[77]
  the anti-hypertensive 
agent, atenolol.
[78-79]
  In addition, prodrugs for masking the bitter sensation of the pain killer 
and the antibacterial drugs, cefuroxime, amoxicillin and cephalexin were also designed and 
made,
[80]
  The linker’s role in atenolol, paracetamol and the antibacterial prodrugs is to block 
the free hydroxyl or amine groups, which are responsible for the drug bitterness, and to 
enable the release of the drug in a programmable manner. Menger’s Kemp acid enzyme 
model was utilized for the design of prodrugs of the anti-Parkinson’s disease, dopamine. [81] 
Prodrug of dimethyl fumarate for the treatment psoriasis was also made and studied.
[82]
 
Furthermore, unraveling the mechanism of Kirby’s acetals has led to the design and synthesis 
of novel prodrugs of the anti-myelodysplastic aza-nucleosides,
[83]
 anti-malarial atovaquone, 
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[84-86]
 anti-cholesterol agents, statins. 
[87]
 and the anti-congestant, phenylephrine. 
[88] 
 In these 
prodrugs, the enzyme model (linker) was covalently attached to the hydroxyl group of the 
active parent drug such that the drug-linker moiety (prodrug) has the potential to cleave upon 
exposure to physiological environments such as stomach, intestine, and/or blood circulation, 
with rates that are only dependent on the structural features of the pharmacologically inactive 
linker (Kirby’s enzyme model).[89-90] 
 
Continuing our study on how to utilize enzyme models as potential carriers for drugs 
containing amine group, we have utilized the proton transfer reaction in the acid-catalyzed 
hydrolysis of N-alkyl maleamic acids (Kirby’s enzyme model) [55]  to design and synthesize 
prodrugs and codrugs of mefenamic and tranexamic acids. 
 
The main goal of our research was to provide drugs and codrugs of mefenamic acid lacking 
any gastrointestinal toxicity side effects while retaining the anti-inflammatory and analgesic 
activity of the active parent drug. In addition, the proposed mefenamic acid prodrugs and 
codrugs should have the potential to undergo a chemical and not enzymatic driven cleavage, 
and release the active parent drug, mefenamic acid, in a controlled manner. 
 
For fulfilling this goal two mefenamic acid amide prodrug and codrug were synthesized by 
reacting the acyl chloride of mefenamic acid with either tranexamic acid (Figure 4) or 
N,Ndimethyl amine (Figure 5). The hydrolysis reactions of the new synthesized codrug 10 
and mefenamic acid amide prodrug 11 at a wide pH range were monitored by HPLC and the 
results obtained are listed in Tables 1 and 2 
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2. Oxalylchloride
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H3C
H3C
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N
H
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Figure 4: Synthesis pathway for mefenamic-tranexamic acids codrug, 10. 
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Table 1: Hydrolysis of codrug 10 at different pHs 
Medium Kobs (h
-1
) t1/2 (h) 
1N HCl 7.25x10
-4
 1.07 
Buffer pH 2.5 No reaction No reaction 
Buffer pH 5.5 No reaction No reaction 
Buffer pH 7.4 No reaction No reaction 
 
 
H3C
H3C
HN
O
OH
H3C
H3C
HN
O
Cl
H3C
H3C
HN
O
N
H3C CH3
H
N
CH3H3C
2.
1. Dichloromethane
2. Oxalylchloride
3. DMF
1. Dichloromethane
11
 
 
Figure 5: Synthesis pathway for tranexamic acid- N,N-Dimethylamide prodrug, 11 
 
Table 2: Hydrolysis of prodrug 11 at different pHs 
 
 
 
 
 
 
SUMMARY & CONCLUSIONS 
In this mini review we have succeeded to cover most of mefenamic acid prodrugs and 
codrugs which have been synthesized during the past twenty years with the aim to provide 
molecules having the same anti-inflammatory and analgesic activity of mefenamic acid, but 
Medium Kobs (h
-1
) t1/2 (h) 
1N HCl 1.14x10
-4
 11.4 
Buffer pH 2.5 No reaction No reaction 
Buffer pH 5.5 No reaction No reaction 
Buffer pH 7.4 No reaction No reaction 
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lacking the gastrointestinal adverse effects associated with the use of NSAIDs in general and 
mefenamic acid in particular. 
 
Most of the mefenamic acid prodrugs and codrugs described in this mini-review were 
synthesized by the classic prodrug approach, by which the active parent drug is attached to a 
promoiety or another active drug directly or via a spacer which upon exposure to 
physiological environment undergoes an enzymatic catalyzed cleavage and releases the active 
parent drug. This approach involves enzyme catalysis which has many disadvantages due to 
many intrinsic and extrinsic factors that can affect the process. For instance, the activity of 
many prodrug-activating enzymes may be varied due to genetic polymorphisms, age-related 
physiological changes, or drug interactions, leading to variation in clinical effects. Therefore, 
there is a need to develop prodrugs that have the potential to undergo interconversion to their 
parent drugs via intramolecular reaction and without the need for enzyme catalysis The 
modern computational approach which has been utilized by Karaman’s group considers 
attaching a designed linker to an active drug, such as NSAIDs, that has poor bioavailability 
and/or toxic side effects, and releasing the parent drug via intramolecular chemical reaction 
without the involvement of metabolic enzymes. With the possibility of designing prodrugs 
with different linkers, the release rate of the parent drug can be controlled and the 
disadvantages associated with the metabolic enzymes will be eliminated. 
 
Advances must be made in understanding the chemistry of many organic reactions that can be 
effectively utilized to enable the development of even more types of prodrugs. The 
understanding of organic reaction mechanisms of certain processes, particularly 
intramolecular reactions, will be the next major milestone in the field of prodrug design and 
development. 
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